Mental health studies with practical context.

A placebo controlled study of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of Suicide prevention or aggression. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis

This study has finished and is no longer accepting participants.

Countries

Australia

Sponsor

Orygen

Adjunct herbal medicine formulation for depression

This study ended early.

Countries

Australia

Sponsor

Integria Healthcare (Australia) Pty. Ltd.

A study comparing a brief wellbeing intervention delivered by coaches with a self-directed intervention to promote recovery in Victorian regional and rural communities impacted by bushfires, drought, and COVID-19.

This study has finished and is no longer accepting participants.

Countries

Australia

Sponsor

Phoenix Australia, Melbourne University

A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Sweden

Sponsor

Eli Lilly Sweden AB

A randomised, double blind, double-dummy, parallel group study to compare the efficacy and tolerability of morphine sulphate prolonged release capsules and methadone oral solution in once per day a...

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom

Sponsor

Napp Pharmaceuticals Research Limited

A randomised, double-blind, parallel-group, active controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with par...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Belgium, Bulgaria, Czechia, + 4 others

Sponsor

H. Lundbeck A/S

A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom, Belgium, Austria, + 9 others

Sponsor

H. Lundbeck A/S

A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, Czechia, Spain

Sponsor

H. Lundbeck A/S

A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, Belgium, Germany, + 2 others

Sponsor

H. Lundbeck A/S

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine combination or Paroxetine monotherapy to Placebo in Patients...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Denmark, Germany

Sponsor

GlaxoSmithKline Research & Development Limited

A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Belgium, Estonia, Finland, + 5 others

Sponsor

H. Lundbeck A/S

Lorazepam for anxiety

This study has finished and is no longer accepting participants.

Countries

Australia

Sponsor

Peter MacCallum Cancer Centre